Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MITCHELL S FINEMAN

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1013965276
CMS profile
506164
Location
PLYMOUTH MEETING, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$53.48

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $53.48 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Boston Scientific Corporation $53.48 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MITCHELL S FINEMAN

NPI 1013965276 · CMS profile ID 506164

Allopathic & Osteopathic Physicians / Ophthalmology

PLYMOUTH MEETING, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013965276?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MITCHELL S FINEMAN, NPI 1013965276, CMS profile ID 506164. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013965276?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MITCHELL S FINEMAN, NPI 1013965276, CMS profile ID 506164. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013965276?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MITCHELL S FINEMAN, NPI 1013965276, CMS profile ID 506164, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1013965276?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $53.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $53.4806/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092327834 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2023 $67.45 1
PY2024 $53.48 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $72,409.50 32
PY2024 Principal investigator $188,294.00 62
PY2023 Principal investigator $424,714.81 16
PY2022 Principal investigator $247,264.20 17
PY2021 Principal investigator $165,530.50 9
PY2020 Principal investigator $169,017.37 5
PY2019 Principal investigator $45,091.80 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,600.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939632
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939634
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,600.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939636
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939642
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939646
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939660
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939662
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939670
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939678
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,600.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939680
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939686
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939688
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,600.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939694
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939698
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939706
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939712
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939714
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,600.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939716
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939736
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939740
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939742
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939754
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939778
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939784
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939786
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,600.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939788
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939792
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939796
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939802
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939804
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939806
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939808
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,600.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939832
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,130.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939836
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,965.00 12/18/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939844
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,000.00 12/02/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939652
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,950.00 12/02/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939726
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,950.00 12/02/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939750
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,000.00 12/02/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939780
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,950.00 12/02/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939790
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,750.00 12/02/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939824
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,750.00 12/02/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939830
Principal investigator 1 Apellis Pharmaceuticals, Inc. $20,756.70 11/01/2024 Non-covered Recipient Entity
MID ATLANTIC RETINA
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1154938848
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,950.00 09/26/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939626
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,750.00 09/26/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939650
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,000.00 09/26/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939668
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,750.00 09/26/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939730
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,000.00 09/26/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939770
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,000.00 09/26/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939818
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,750.00 09/26/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939838
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,750.00 08/21/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939728
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,750.00 08/21/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939764
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,950.00 08/21/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939794
Principal investigator 1 Apellis Pharmaceuticals, Inc. $590.80 07/26/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939682
Principal investigator 1 Genentech, Inc. $5,250.00 07/24/2024 Non-covered Recipient Entity
MID ATLANTIC RETINA RETINAVITREOUS ASSOC LTD
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD No dispute reported 06/30/2026 1133404084
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,000.00 07/17/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939658
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,000.00 07/17/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939666
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,750.00 07/17/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939732
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,000.00 07/17/2024 Non-covered Recipient Entity
Retinovitreous Associates, LTD
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1154939734
Principal investigator 1 Genentech, Inc. $592.00 07/05/2024 Non-covered Recipient Entity
MID ATLANTIC RETINA RETINAVITREOUS ASSOC LTD
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD No dispute reported 06/30/2026 1133404086
Principal investigator 1 Genentech, Inc. $3,925.50 06/20/2024 Non-covered Recipient Entity
MID ATLANTIC RETINA RETINAVITREOUS ASSOC LTD
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD No dispute reported 06/30/2026 1133404076
Principal investigator 1 Genentech, Inc. $5,899.00 01/29/2024 Non-covered Recipient Entity
MID ATLANTIC RETINA RETINAVITREOUS ASSOC LTD
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD No dispute reported 06/30/2026 1133404070